Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction

Macrophage immune checkpoint inhibitors, such as anti-CD47 antibodies, show promise in clinical trials for solid and hematologic malignancies. However, the best strategies to use these therapies remain unknown and ongoing studies suggest they may be most effective when used in combination with other...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaccaro, Kyle, Allen, Juliet, Whitfield, Troy W., Maoz, Asaf, Reeves, Sarah, Velarde, José, Yang, Dian, Phan, Nicole, Bell, George W., Hata, Aaron N., Weiskopf, Kipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028834/
https://www.ncbi.nlm.nih.gov/pubmed/36945559
http://dx.doi.org/10.1101/2023.03.03.531059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028834/
https://www.ncbi.nlm.nih.gov/pubmed/36945559
http://dx.doi.org/10.1101/2023.03.03.531059

Ejemplares similares